Foundayo: The Ultimate Guide to the New Weight-Loss Pill

The U.S. Food and Drug Administration (FDA) has fast-tracked the approval of a new weight-loss medication from Eli Lilly, marking it as the second daily oral treatment for obesity and related health conditions. The drug, known as orforglipron, is a GLP-1 medication that mimics a natural hormone responsible for regulating appetite and feelings of fullness. It operates in a similar way to injectable treatments that are currently widely used.

Shipments of Foundayo, the brand name for orforglipron, are expected to begin this Monday. Eli Lilly has announced that insured patients will be able to access the medication at a monthly cost ranging from $149 to $349, depending on the prescribed dose. This new option joins Novo Nordisk’s oral Wegovy, which has already seen over 600,000 prescriptions in the U.S. since its December approval.

The FDA granted the approval as part of an initiative designed to reduce the time required for drug reviews. In this case, the agency evaluated Eli Lilly’s application within 50 days, demonstrating a commitment to expediting the availability of innovative treatments.

A clinical trial involving more than 3,000 adults with obesity showed significant results. Participants who received the highest dose of orforglipron, 36 milligrams, experienced an average weight loss of 11.2% — roughly 25 pounds — over a period of more than 16 months. This was compared to a 2.1% weight loss, or less than 5 pounds, among those who took a placebo.

While both Eli Lilly’s and Novo Nordisk’s pills offer convenience, orforglipron stands out as a small-molecule GLP-1 drug that can be taken without restrictions. In contrast, Wegovy, a peptide-based pill, must be consumed with a sip of water in the morning on an empty stomach, followed by a 30-minute wait before eating or drinking.

Patients taking orforglipron also saw improvements in several health indicators, including waist circumference, blood pressure, triglyceride levels, and cholesterol levels. However, side effects such as gastrointestinal issues led between 5% and 10% of participants in the orforglipron study to discontinue treatment, compared to nearly 3% in the placebo group.

According to a survey by KFF, a nonprofit health policy research group, about one in eight people in the U.S. have used injectable GLP-1 drugs. However, many face challenges in affording these costly treatments.

The pill from Indianapolis-based Eli Lilly will be included in a Trump administration initiative aimed at lowering the prices of GLP-1 drugs. This move is expected to increase accessibility for more patients seeking effective weight-loss solutions.

Pos terkait